to list on 16th, page-23

just in on the email from Prima ...

" Australian healthcare company Prima BioMed Ltd (ASX: PRR) (Prima) is pleased to announce that it will commence trading on the NASDAQ Stock Market (NASDAQ) on Monday, April 16, 2012 (U.S. Eastern Time).

Key points
· Prima BioMed Ltd will commence trading of its American Depositary Receipts (ADR) on the NASDAQ Stock Market, on Monday, April 16 (U.S. Eastern Time).
· A registration statement relating to the ADR’s has been filed with, and declared effective by, the U.S. Securities and Exchange Commission.
· Prima will trade under the code PBMD on the NASDAQ.
· Upon listing on the NASDAQ, the Company will have dual listings of its securities on both the Australian Securities Exchange (ASX) and NASDAQ.
· Every one Prima ADR on the NASDAQ will represent 30 common Prima shares.
· The NASDAQ listing is a Level II ADR compliance listing and is being managed by Bank of New York Mellon, who will be Prima’s deposit agent for converting the Company’s common shares into ADRs.
· Deutsche Bank Securities Inc., Noble Financial Capital Markets and Aegis Capital will act as market makers for Prima in the United States.
· Prima is the first Australian U.S. listing in more than two years and the Company stands to benefit greatly from the exposure to this major capital market.

Prima BioMed chief executive officer Martin Rogers said:
“We believe trading alongside our peers in the U.S. will have a significant impact on our valuation and liquidity. The listing on the NASDAQ, comes at a significant point in the development timeline for CVac™ and the timing should offer U.S, investors an opportunity to share in this growth phase of the Company."

About Prima BioMed
Prima BioMed is an ASX listed Australian health care company. The Company is focused on technologies in the fields of cancer immunotherapy and immunology. Its lead product is CVacTM ovarian cancer therapy treatment. It is currently undertaking late-stage clinical trials and is progressing toward eventual commercialisation in the United States, Australia, Europe, and globally. The Company’s broader, long term goal is to develop commercial cancer treatment technologies and programs for global markets. "


so watch the opening bell of Prima in the US -- PBMD

wonder if will list at a Premium ...

(NASDAQ) on Monday, April 16, 2012 (U.S. Eastern Time).